Simple Summary Although the extensive use of highly active oncological treatments has led to an increased rate of secondary resections in patients with colorectal liver metastases, it has led to questions regarding the correct surgical management of disappearing liver metastases (DLM) and small residual lesions during chemotherapy. Our study aimed to evaluate the clinical outcome of DLM and small remnant liver metastases (<= 10 mm) assessed by means of hepatobiliary contrast-enhanced and diffusion-weighted MR imaging (DW-MRI) in metastatic colorectal cancer patients with first-line chemotherapy treatment in order to support the clinical management and decision-making process for these liver lesions. Our results showed that DLM assessed via hepatobiliary contrast-enhanced and DW-MRI very probably indicate a complete response in patients without chemotherapy-induced sinusoidal obstruction syndrome. In these patients, a follow-up with liver MRI can be considered, and resection should be performed in the case of disease relapse. The surgical removal of small remnants of liver metastases should always be advocated whenever technically possible. We aimed to evaluate the outcome of the disappearance or small remnants of colorectal liver metastases during first-line chemotherapy assessed by hepatobiliary contrast-enhanced and diffusion-weighted MR imaging (DW-MRI). Consecutive patients with at least one disappearing liver metastasis (DLM) or small residual liver metastases (<= 10 mm) assessed by hepatobiliary contrast-enhanced and DW-MRI during first-line chemotherapy were included. Liver lesions were categorized into three groups: DLM; residual tiny liver metastases (RTLM) when <= 5 mm; small residual liver metastases (SRLM) when >5mm and <= 10 mm. The outcome of resected liver metastases was assessed in terms of pathological response, whereas lesions left in situ were evaluated in terms of local relapse or progression. Fifty-two outpatients with 265 liver lesions were radiologically reviewed; 185 metastases fulfilled the inclusion criteria: 40 DLM, 82 RTLM and 60 SRLM. We observed a pCR rate of 75% (3/4) in resected DLM and 33% (12/36) of local relapse for DLM left in situ. We observed a risk of relapse of 29% and 57% for RTLM and SRLM left in situ, respectively, and a pCR rate of about 40% overall for resected lesions. DLM assessed via hepatobiliary contrast-enhanced and DW-MRI very probably indicates a complete response. The surgical removal of small remnants of liver metastases should always be advocated whenever technically possible.

Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging

Masi, Gianluca;Cremolini, Chiara;
2023-01-01

Abstract

Simple Summary Although the extensive use of highly active oncological treatments has led to an increased rate of secondary resections in patients with colorectal liver metastases, it has led to questions regarding the correct surgical management of disappearing liver metastases (DLM) and small residual lesions during chemotherapy. Our study aimed to evaluate the clinical outcome of DLM and small remnant liver metastases (<= 10 mm) assessed by means of hepatobiliary contrast-enhanced and diffusion-weighted MR imaging (DW-MRI) in metastatic colorectal cancer patients with first-line chemotherapy treatment in order to support the clinical management and decision-making process for these liver lesions. Our results showed that DLM assessed via hepatobiliary contrast-enhanced and DW-MRI very probably indicate a complete response in patients without chemotherapy-induced sinusoidal obstruction syndrome. In these patients, a follow-up with liver MRI can be considered, and resection should be performed in the case of disease relapse. The surgical removal of small remnants of liver metastases should always be advocated whenever technically possible. We aimed to evaluate the outcome of the disappearance or small remnants of colorectal liver metastases during first-line chemotherapy assessed by hepatobiliary contrast-enhanced and diffusion-weighted MR imaging (DW-MRI). Consecutive patients with at least one disappearing liver metastasis (DLM) or small residual liver metastases (<= 10 mm) assessed by hepatobiliary contrast-enhanced and DW-MRI during first-line chemotherapy were included. Liver lesions were categorized into three groups: DLM; residual tiny liver metastases (RTLM) when <= 5 mm; small residual liver metastases (SRLM) when >5mm and <= 10 mm. The outcome of resected liver metastases was assessed in terms of pathological response, whereas lesions left in situ were evaluated in terms of local relapse or progression. Fifty-two outpatients with 265 liver lesions were radiologically reviewed; 185 metastases fulfilled the inclusion criteria: 40 DLM, 82 RTLM and 60 SRLM. We observed a pCR rate of 75% (3/4) in resected DLM and 33% (12/36) of local relapse for DLM left in situ. We observed a risk of relapse of 29% and 57% for RTLM and SRLM left in situ, respectively, and a pCR rate of about 40% overall for resected lesions. DLM assessed via hepatobiliary contrast-enhanced and DW-MRI very probably indicates a complete response. The surgical removal of small remnants of liver metastases should always be advocated whenever technically possible.
2023
Boraschi, Piero; Moretto, Roberto; Donati, Francescamaria; Borelli, Beatrice; Mercogliano, Giuseppe; Giugliano, Luigi; Boccaccino, Alessandra; Della P...espandi
File in questo prodotto:
File Dimensione Formato  
cancers-15-02200.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Creative commons
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1184413
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact